{"id":"inhaled-long-acting-muscarinic-antagonist","safety":{"commonSideEffects":[{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Urinary retention"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL4303227","moleculeType":"Small molecule","molecularWeight":"951.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Long-acting muscarinic antagonists (LAMAs) inhibit M3 muscarinic receptors on airway smooth muscle and mucus-secreting cells, preventing acetylcholine-induced contraction and secretion. When inhaled, they provide sustained bronchodilation over 24 hours, improving airflow and reducing symptoms in obstructive airway diseases. This mechanism is particularly effective in COPD and asthma where cholinergic tone contributes to airway obstruction.","oneSentence":"Blocks muscarinic acetylcholine receptors in the airways to reduce bronchoconstriction and mucus secretion in chronic respiratory diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:12.580Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma (as add-on therapy)"}]},"trialDetails":[{"nctId":"NCT06712563","phase":"","title":"Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2000},{"nctId":"NCT07073950","phase":"PHASE4","title":"A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":"Chronic Obstructive Pulmonary Disease, Hyperinflation","enrollment":56},{"nctId":"NCT03963167","phase":"","title":"Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)","status":"COMPLETED","sponsor":"Chiesi Italia","startDate":"2019-08-21","conditions":"COPD","enrollment":661},{"nctId":"NCT07406048","phase":"","title":"Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients","status":"NOT_YET_RECRUITING","sponsor":"Chiesi Farmaceutica Ltda.","startDate":"2026-01-30","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":396},{"nctId":"NCT07396987","phase":"NA","title":"Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Juan Carlos Cardet","startDate":"2026-02","conditions":"Asthma Attack, Asthma Control, Asthma Exacerbations","enrollment":40},{"nctId":"NCT07396311","phase":"","title":"Fractional Exhaled Nitric Oxide and Exacerbations of COPD","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2026-03-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":120},{"nctId":"NCT07329946","phase":"NA","title":"Immuno-inflammatory Response of Erdosteine in COPD","status":"NOT_YET_RECRUITING","sponsor":"Pierachille Santus, MD, PhD","startDate":"2026-02-28","conditions":"COPD","enrollment":30},{"nctId":"NCT07288827","phase":"NA","title":"Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia","status":"RECRUITING","sponsor":"Indiana University","startDate":"2023-05-04","conditions":"Primary Ciliary Dyskinesia, Healthy","enrollment":40},{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT07198880","phase":"NA","title":"Impact of Home Non Invasive Ventilation in Patients With Chronic Obstructive Pulmonary Disease Discharged From Assiut University Hospital","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-01-01","conditions":"COPD, COPD (Chronic Obstructive Pulmonary Disease), Ventilation Therapy","enrollment":40},{"nctId":"NCT07192016","phase":"PHASE4","title":"129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2026-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":60},{"nctId":"NCT06340581","phase":"PHASE1","title":"A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2024-10-17","conditions":"Healthy","enrollment":""},{"nctId":"NCT04315558","phase":"PHASE2","title":"Revefenacin in Acute Respiratory Insufficiency in COPD","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2020-11-01","conditions":"COPD, Acute Respiratory Failure","enrollment":21},{"nctId":"NCT06297668","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":42},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT07030881","phase":"NA","title":"Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-06-20","conditions":"Asthma, COPD","enrollment":380},{"nctId":"NCT04456673","phase":"PHASE3","title":"Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-07-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":935},{"nctId":"NCT06552364","phase":"PHASE4","title":"Air Pollution and Inhaled Corticosteroids in COPD","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-04-01","conditions":"COPD","enrollment":48},{"nctId":"NCT05563675","phase":"PHASE4","title":"Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause","status":"COMPLETED","sponsor":"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","startDate":"2023-01-27","conditions":"COPD Exacerbation","enrollment":10011},{"nctId":"NCT05046795","phase":"PHASE3","title":"Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2021-11-10","conditions":"COPD","enrollment":258},{"nctId":"NCT03930732","phase":"PHASE3","title":"Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-04-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":939},{"nctId":"NCT03527927","phase":"NA","title":"sTep dOWn Inhalers in the reAl woRlD","status":"COMPLETED","sponsor":"Hywel Dda Health Board","startDate":"2017-05-17","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":67},{"nctId":"NCT05927155","phase":"PHASE3","title":"Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD","status":"COMPLETED","sponsor":"Erasme University Hospital","startDate":"2021-06-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":30},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT03265145","phase":"PHASE4","title":"Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-09-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":714},{"nctId":"NCT04172701","phase":"","title":"A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":9284},{"nctId":"NCT02948959","phase":"PHASE3","title":"Evaluation of Dupilumab in Children With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-04-21","conditions":"Asthma","enrollment":408},{"nctId":"NCT05145894","phase":"","title":"Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device","status":"UNKNOWN","sponsor":"Healthy Networks","startDate":"2021-09-30","conditions":"Asthma, COPD","enrollment":200},{"nctId":"NCT03627858","phase":"","title":"Fixed Dose Triple Therapy in Severe Chronic Obstructive Pulmonary Disease in a Real World Setting","status":"COMPLETED","sponsor":"Chiesi SA/NV","startDate":"2018-08-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":149},{"nctId":"NCT04184297","phase":"","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":27190},{"nctId":"NCT02512198","phase":"NA","title":"Electronic Prescription Data to Improve Primary Care Prescribing","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2015-07","conditions":"Physician's Practice Patterns","enrollment":236},{"nctId":"NCT03250689","phase":"PHASE2","title":"Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-11-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":19},{"nctId":"NCT01068613","phase":"PHASE2","title":"Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":62},{"nctId":"NCT03645434","phase":"PHASE2","title":"A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-10-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":73},{"nctId":"NCT03034967","phase":"PHASE2","title":"Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-04-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":614},{"nctId":"NCT03114969","phase":"","title":"Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":450},{"nctId":"NCT02147015","phase":"NA","title":"Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD","status":"COMPLETED","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2014-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":248},{"nctId":"NCT00749411","phase":"PHASE2","title":"Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":61},{"nctId":"NCT04456205","phase":"","title":"Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease (COPD)","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-10-01","conditions":"COPD, Inhaled Corticosteroid","enrollment":200},{"nctId":"NCT02184611","phase":"PHASE3","title":"A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":308},{"nctId":"NCT02488590","phase":"","title":"Systematic Approach for the Diagnosis and Treatment of Obstructive Lung Diseases","status":"UNKNOWN","sponsor":"KU Leuven","startDate":"2015-07","conditions":"Chronic Obstructive Pulmonary Disease, Asthma, Overlap Syndrome","enrollment":180},{"nctId":"NCT03724877","phase":"","title":"Effectiveness of Triple Therapy in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-11-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":8853},{"nctId":"NCT02971293","phase":"PHASE2","title":"Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-12-15","conditions":"Chronic Obstructive Pulmonary Disease COPD","enrollment":42},{"nctId":"NCT02567214","phase":"PHASE4","title":"Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Laval University","startDate":"2016-06","conditions":"COPD","enrollment":50},{"nctId":"NCT02039011","phase":"PHASE4","title":"Ultra-long Acting Bronchodilator Therapy in Asthmatics","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2014-02","conditions":"Asthma","enrollment":14},{"nctId":"NCT01985334","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02-14","conditions":"COPD","enrollment":4389},{"nctId":"NCT02814656","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-22","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":24},{"nctId":"NCT02236611","phase":"PHASE4","title":"A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-26","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1036},{"nctId":"NCT02014480","phase":"PHASE3","title":"A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":207},{"nctId":"NCT02796651","phase":"PHASE2","title":"Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-30","conditions":"Chronic Obstructive Pulmonary Disease - COPD","enrollment":132},{"nctId":"NCT01772134","phase":"PHASE3","title":"Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":617},{"nctId":"NCT02207829","phase":"PHASE3","title":"A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1017},{"nctId":"NCT01899742","phase":"PHASE3","title":"The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":497},{"nctId":"NCT01777334","phase":"PHASE3","title":"The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":905},{"nctId":"NCT02152605","phase":"PHASE3","title":"A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":498},{"nctId":"NCT01372410","phase":"PHASE2","title":"A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":163},{"nctId":"NCT03159442","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-06-19","conditions":"Chronic Obstructive Pulmonary Disease - COPD","enrollment":25},{"nctId":"NCT01491802","phase":"PHASE3","title":"Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD","status":"COMPLETED","sponsor":"Queen's University","startDate":"2012-01","conditions":"COPD","enrollment":17},{"nctId":"NCT00964405","phase":"PHASE1","title":"Phase I Study of GSK233705 in Healthy Japanese Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":28},{"nctId":"NCT01691547","phase":"PHASE1","title":"A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":44},{"nctId":"NCT00783003","phase":"PHASE1","title":"A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT00976144","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT02953041","phase":"PHASE4","title":"Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2016-10","conditions":"Asthma","enrollment":31},{"nctId":"NCT01875003","phase":"PHASE3","title":"A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-08-31","conditions":"Asthma","enrollment":348},{"nctId":"NCT01772147","phase":"PHASE3","title":"Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":608},{"nctId":"NCT02837380","phase":"PHASE1","title":"A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT00784550","phase":"PHASE4","title":"A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":342},{"nctId":"NCT02622243","phase":"PHASE4","title":"Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2015-11","conditions":"Asthma","enrollment":13},{"nctId":"NCT02546349","phase":"PHASE4","title":"Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2014-07","conditions":"COPD","enrollment":143},{"nctId":"NCT02127697","phase":"PHASE3","title":"Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-03","conditions":"Asthma","enrollment":""},{"nctId":"NCT01763463","phase":"","title":"WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1},{"nctId":"NCT01205269","phase":"PHASE2","title":"The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":28},{"nctId":"NCT00939211","phase":"PHASE2","title":"The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Inhaled Long-Acting Muscarinic Antagonist","genericName":"Inhaled Long-Acting Muscarinic Antagonist","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Blocks muscarinic acetylcholine receptors in the airways to reduce bronchoconstriction and mucus secretion in chronic respiratory diseases. Used for Chronic obstructive pulmonary disease (COPD), Asthma (as add-on therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}